<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869141</url>
  </required_header>
  <id_info>
    <org_study_id>UCLA IRB#08-10-110-01</org_study_id>
    <nct_id>NCT00869141</nct_id>
  </id_info>
  <brief_title>Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma</brief_title>
  <official_title>Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the occurrence rate of the high pressure phase and
      the final pressure outcomes between patients treated with glaucoma medication prior to the
      expected onset of the high pressure phase to those patients who have glaucoma medication
      started at the onset of the high pressure phase. The investigators hypothesize that if
      glaucoma medications are started prior to the expected onset of high pressure phase, the high
      pressure phase will not occur as frequently and the ultimate pressure level will be lower
      than if the glaucoma medications are started at the onset of this phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tube shunt procedures are a popular surgery for the control of glaucoma. Tube shunt devices
      are designed to drain eye fluid (aqueous humor) through a tube inserted into the front
      chamber of the eye (anterior chamber) to a plate secured to the mid-posterior section of the
      outer eyeball wall. The body then lays down collagen tissue and forms a capsule around the
      plate. The fluid filters through the capsule of collagen tissue and is reabsorbed into the
      ocular and systemic circulation. The collagen tissue continues to remodel itself over a long
      period of time (up to years). However, a well characterized, yet poorly understood,
      phenomenon occurs in many patients in the 4-8 weeks after the device's implantation, called
      the hypertensive phase. The pressure of the eye can increase from a desirable level of about
      10 immediately after the tube shunt implantation to much higher levels, in the range of 20 to
      30's, and then it may gradually return to less than 20. Such a high pressure phase can cause
      irreversible damage an eye with glaucoma. The usual management of a high pressure phase is to
      start glaucoma medications as soon as it is detected. A previous study we conducted showed
      that this high pressure phase resolves in about half of patients with medical therapy, but
      the other half may continue to have higher than expected pressures. The exact cause of this
      high pressure phase is unknown. However, it is postulated that the mechanism may involve a
      compaction collagen tissue layers under the eye's own fluid pressure while the collagen
      tissue is being laid down, which in turn creates a firm, dense capsule that makes escape of
      fluid difficult. Therefore, it is argued that if the formation of eye fluid is reduced by
      medication during this initial period when the collagen tissue is laid down, the compaction
      of collagen, and subsequently the high pressure phase may be avoided.

      The purpose of this study is to compare the occurrence rate of the high pressure phase and
      the final pressure outcomes between patients treated with glaucoma medication prior to the
      expected onset of the high pressure phase to those patients who have glaucoma medication
      started at the onset of the high pressure phase. We hypothesize that if glaucoma medications
      are started prior to the expected onset of high pressure phase, the high pressure phase will
      not occur as frequently and the ultimate pressure level will be lower than if the glaucoma
      medications are started at the onset of this phase.

      We believe that this study will have a very significant impact on the management of glaucoma
      with tube shut procedures. If it is true that the rate and pressure level of the hypertensive
      phase can be reduced by simply starting glaucoma medications to reduce the formation of eye
      fluid before the expected the high pressure phase begins, which is generally 4 weeks after
      implantation of the tube shunt device, glaucoma patients can be saved from exposure to the
      very high level of eye pressure, and the eventual pressure control may be better.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma</measure>
    <time_frame>within 6 months after surgery</time_frame>
    <description>Intraocular pressure more than 21 mmHg during the first 6 months after Ahmed valve implantation after the pressure has been reduced to less than 22 mmHg in the first postoperative week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular Pressure Control After Ahmed Valve Implantation for Glaucoma</measure>
    <time_frame>3 weeks after surgery</time_frame>
    <description>intraocular pressure comparison between groups after the Ahmed valve implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular Pressure of Eyes With Hypertensive Phase Versus Without Hypertensive Phase</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>intraocular pressure of eyes with hypertensive phase versus without hypertensive phase</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Research arm (postop IOP&gt;10)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive glaucoma medications if the eye pressure more than 10 mmHg after AHmed valve implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care arm (postop IOP&gt;17)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receive glaucoma medication if eye pressure more than 17 mmHg after Ahmed valve implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)</intervention_name>
    <description>Subjects may receive glaucoma medications after Ahmed valve implantation</description>
    <arm_group_label>Research arm (postop IOP&gt;10)</arm_group_label>
    <arm_group_label>Standard of care arm (postop IOP&gt;17)</arm_group_label>
    <other_name>Timolol, Brimonidine, Dorzolamide, Brinzolamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients requiring Ahmed glaucoma valve implantation to control intraocular pressure
             between the ages of 18 and 85 years.

        Exclusion Criteria:

          1. Unwilling or unable to give consent or unwilling to accept randomization.

          2. Patient out of area and potentially unavailable for follow-up visits.

          3. Known allergic reaction to timolol, brimonidine, dorzolamide, brinzolamide, or sulfa
             drugs.

          4. Known medical contraindications to the use of beta-blockers, including congestive
             heart failure, heart block, asthma, and chronic obstructive pulmonary disease.

          5. Concurrent intraocular procedure with Ahmed glaucoma valve implantation

          6. Previous Ahmed glaucoma valve implantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon K Law, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Stein Eye Institute, University of California Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juels Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.jsei.org/</url>
    <description>Jules Stein Eye Institute</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <results_first_submitted>June 1, 2015</results_first_submitted>
  <results_first_submitted_qc>June 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2015</results_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Simon Law</investigator_full_name>
    <investigator_title>Clinical Associate Professor of Health Sciences</investigator_title>
  </responsible_party>
  <keyword>Glaucoma tube shunt procedure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Research Arm</title>
          <description>Receive glaucoma medications if the eye pressure more than 10 mmHg after AHmed valve implantation
glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide): Subjects may receive glaucoma medications after Ahmed valve implantation</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care Arm</title>
          <description>Receive glaucoma medication if eye pressure more than 17 mmHg after Ahmed valve implantation
glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide): Subjects may receive glaucoma medications after Ahmed valve implantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Research Arm</title>
          <description>Receive glaucoma medications if the eye pressure more than 10 mmHg after AHmed valve implantation
glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide): Subjects may receive glaucoma medications after Ahmed valve implantation</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care Arm</title>
          <description>Receive glaucoma medication if eye pressure more than 17 mmHg after Ahmed valve implantation
glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide): Subjects may receive glaucoma medications after Ahmed valve implantation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="11.6"/>
                    <measurement group_id="B2" value="61.6" spread="15.3"/>
                    <measurement group_id="B3" value="64.3" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma</title>
        <description>Intraocular pressure more than 21 mmHg during the first 6 months after Ahmed valve implantation after the pressure has been reduced to less than 22 mmHg in the first postoperative week</description>
        <time_frame>within 6 months after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Research Arm</title>
            <description>Receive glaucoma medications if the eye pressure more than 10 mmHg after AHmed valve implantation
glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide): Subjects may receive glaucoma medications after Ahmed valve implantation</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Arm</title>
            <description>Receive glaucoma medication if eye pressure more than 17 mmHg after Ahmed valve implantation
glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide): Subjects may receive glaucoma medications after Ahmed valve implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Hypertensive Phase After Ahmed Valve Implantation for Glaucoma</title>
          <description>Intraocular pressure more than 21 mmHg during the first 6 months after Ahmed valve implantation after the pressure has been reduced to less than 22 mmHg in the first postoperative week</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intraocular Pressure Control After Ahmed Valve Implantation for Glaucoma</title>
        <description>intraocular pressure comparison between groups after the Ahmed valve implantation</description>
        <time_frame>3 weeks after surgery</time_frame>
        <population>Eye pressure at postop 3-week is reported</population>
        <group_list>
          <group group_id="O1">
            <title>Research Arm</title>
            <description>Receive glaucoma medications if the eye pressure more than 10 mmHg after AHmed valve implantation
glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide): Subjects may receive glaucoma medications after Ahmed valve implantation</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Arm</title>
            <description>Receive glaucoma medication if eye pressure more than 17 mmHg after Ahmed valve implantation
glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide): Subjects may receive glaucoma medications after Ahmed valve implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure Control After Ahmed Valve Implantation for Glaucoma</title>
          <description>intraocular pressure comparison between groups after the Ahmed valve implantation</description>
          <population>Eye pressure at postop 3-week is reported</population>
          <units>mmHg at postop 3-week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="3.6"/>
                    <measurement group_id="O2" value="20.6" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intraocular Pressure of Eyes With Hypertensive Phase Versus Without Hypertensive Phase</title>
        <description>intraocular pressure of eyes with hypertensive phase versus without hypertensive phase</description>
        <time_frame>1 year after surgery</time_frame>
        <population>Please note that these two groups were different from those groups in previous comparison. The patients that developed hypertensive phase were compared to those that did not developed hypertensive phase, so the number of patients in these two groups and the mean pressure at 1 year +/-standard deviation results were different.</population>
        <group_list>
          <group group_id="O1">
            <title>Hypertensive Phase Group</title>
            <description>Eyes that developed hypertensive phase after Ahmed valve implantation</description>
          </group>
          <group group_id="O2">
            <title>Non-hypertensive Phase Group</title>
            <description>Eyes that did not develop hypertensive phase after Ahmed valve implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure of Eyes With Hypertensive Phase Versus Without Hypertensive Phase</title>
          <description>intraocular pressure of eyes with hypertensive phase versus without hypertensive phase</description>
          <population>Please note that these two groups were different from those groups in previous comparison. The patients that developed hypertensive phase were compared to those that did not developed hypertensive phase, so the number of patients in these two groups and the mean pressure at 1 year +/-standard deviation results were different.</population>
          <units>mmHg in 1 year postop</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="5.2"/>
                    <measurement group_id="O2" value="11.4" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Research Arm</title>
          <description>Receive glaucoma medications if the eye pressure more than 10 mmHg after AHmed valve implantation
glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide): Subjects may receive glaucoma medications after Ahmed valve implantation</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care Arm</title>
          <description>Receive glaucoma medication if eye pressure more than 17 mmHg after Ahmed valve implantation
glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide): Subjects may receive glaucoma medications after Ahmed valve implantation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Uveitis and conreal edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Simon K. Law</name_or_title>
      <organization>Stein Eye Institute</organization>
      <phone>(310)794-1477</phone>
      <email>law@jsei.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

